Allogene Therapeutics, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On June 9, 2023, Eric Schmidt, Ph.D., the Chief Financial Officer, principal financial officer and principal accounting officer of Allogene Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign, effective at the close of business on August 2, 2023, to spend more time with his family.
Extracted from this filing and checked against the source text.
Eric Schmidt resigned as Chief Financial Officer at Allogene Therapeutics, Inc..
On June 9, 2023, Eric Schmidt, Ph.D., the Chief Financial Officer, principal financial officer and principal accounting officer of Allogene Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign, effective at the close of business on August 2, 2023, to spend more time with his family.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.